Biotech Catalyst Daily
The morning catalyst calendar for investors and analysts allocating against FDA decisions, clinical readouts, and the approval cycle that moves the sector.
- PDUFA dates and advisory committee calendars across oncology, rare disease, and neuro.
- Phase II and III readouts with the endpoint context the press release leaves out.
- FDA complete response letters, accelerated approval conversions, and label-expansion moves.
- Licensing deals, M&A, and the Street’s reaction to the day’s biotech prints.
- Written for portfolio managers, analysts, and pharma BD teams — signal over hype.
Recent Editions
- PDUFA watch: this quarter’s binary events across oncology and rare disease.
- FDA AdCom recaps — how the committee votes mapped to approvability reads.
- Accelerated approval conversions in 2026 and what endpoint slippage means for stocks.
- Deal tape — licensing terms, upfronts, and what buyers are signaling on valuation.